Stereotaxis Releases Second Generation V-CAS Deflect™ System in Europe
July 26 2016 - 9:00AM
Stereotaxis, Inc. (NASDAQ:STXS), a global leader in innovative
technologies for the treatment of cardiac arrhythmias, today
announced the market release of its second generation V-CAS
Deflect™ catheter advancement system in Europe. The V-CAS
Deflect catheter advancement system is designed to remotely control
a proprietary robotic deflectable sheath during a cardiac ablation
procedure with the Stereotaxis Niobe® remote magnetic navigation
system. The deflectable sheath provides improved support, stability
and maneuverability of the magnetic ablation catheter during
therapy delivery.
“We have made considerable advancements to our V-CAS Deflect
system design with this latest iteration and are very pleased to
bring physicians even greater access and versatility in magnetic
catheter navigation within all four chambers of the heart,” said
William C. Mills, Stereotaxis Chief Executive Officer. “By remotely
controlling both the magnetic catheter body and deflectable
steering sheath, the V-CAS Deflect system, in combination with the
Niobe system, enables safer, more efficient single-operator
procedures for complex arrhythmias and further progresses our
vision of a fully remote ablation environment.”
Part of the Stereotaxis Vdrive® robotic navigation system
portfolio, the V-CAS Deflect catheter advancement system
incorporates a disposable, deflectable sheath capable of 210-degree
deflection at the distal end. Integrated electrodes on the sheath
are optimized for display on a mapping system, enabling standard
sheath techniques and adjustments to be visualized and performed
from a control room rather than from within the radiation field of
the procedure room. The new version includes features to improve
performance in smaller heart chambers, provide better navigation
through complex anatomy, and enhance visualization on 3D mapping
systems. The use of the V-CAS Deflect system negates the need for
any other type of deflectable sheath when conducting magnetic
procedures.
The enhanced V-CAS Deflect system has already been successfully
utilized in procedures performed at St. Olav’s Hospital in Norway
and Centre Hospitalier Princess Grace in Monaco.
About StereotaxisStereotaxis is a healthcare
technology and innovation leader in the development of robotic
cardiology instrument navigation systems designed to enhance the
treatment of arrhythmias and coronary disease, as well as
information management solutions for the interventional lab. Over
100 issued patents support the Stereotaxis platform, which helps
physicians around the world provide unsurpassed patient care with
robotic precision and safety, improved lab efficiency and
productivity, and enhanced integration of procedural information.
Stereotaxis' core Epoch® Solution includes the Niobe® magnetic
navigation system, the Odyssey® portfolio of lab optimization,
networking and patient information management solutions, and the
Vdrive® robotic navigation system and consumables.
The core components of Stereotaxis’ systems have received
regulatory clearance in the United States, European Union, Canada,
China, Japan, and elsewhere. The V-Sono™ ICE catheter manipulator,
V-Loop™ variable loop catheter manipulator, and V-CAS™ catheter
advancement system have received clearance in the United States,
Canada, and the European Union. The V-CAS Deflect™ catheter
advancement system is available for use in the European Union. For
more information, please visit www.stereotaxis.com.
This press release includes statements that may constitute
"forward-looking" statements, usually containing the words
"believe”, "estimate”, "project”, "expect" or similar expressions.
Forward-looking statements inherently involve risks and
uncertainties that could cause actual results to differ materially
from the forward-looking statements. Factors that would cause or
contribute to such differences include, but are not limited to, the
Company's ability to raise additional capital on a timely basis and
on terms that are acceptable, its continued listing on the NASDAQ
Capital Market, its ability to continue to manage expenses and cash
burn rate at sustainable levels, its ability to continue to work
with lenders to extend, repay or refinance indebtedness on
acceptable terms, continued acceptance of the Company's products in
the marketplace, the effect of global economic conditions on the
ability and willingness of customers to purchase its systems and
the timing of such purchases, competitive factors, changes
resulting from the recently enacted healthcare reform in the United
States, including changes in government reimbursement procedures,
dependence upon third-party vendors, timing of regulatory
approvals, and other risks discussed in the Company's periodic and
other filings with the Securities and Exchange Commission. By
making these forward-looking statements, the Company undertakes no
obligation to update these statements for revisions or changes
after the date of this release. There can be no assurance that the
Company will recognize revenue related to its purchase orders and
other commitments in any particular period or at all because some
of these purchase orders and other commitments are subject to
contingencies that are outside of the Company's control. In
addition, these orders and commitments may be revised, modified,
delayed or canceled, either by their express terms, as a result of
negotiations, or by overall project changes or delays.
Company Contact:
Martin C. Stammer
Chief Financial Officer
314-678-6155
Investor Contact:
Todd Kehrli / Jim Byers
MKR Group, Inc.
323-468-2300
stxs@mkr-group.com